rising strategic initiatives by market players and rising demand for affordable medications is Driving the Global Generic Drugs Market, are expected to drive market expansion in the near future at a CAGR of 9.36% during the forecast period 2025 to 2035

Market Research Future (MRFR) has published a cooked research report on the “Global Generic Drugs Market” that contains information from 2019 to 2035.

The Global Generic Drugs Market is estimated to register a CAGR of 9.36% during the forecast period of 2025 to 2035.

MRFR recognizes the following companies as the key players in the Global Generic Drugs Market— include Sun Pharmaceutical Industries Ltd, Lupin Pharmaceuticals, Inc, Endo International Plc, Urobindo Pharma, Aspen Holdings, Cipla Ltd, Novartis Ag, Teva Pharmaceutical Industries Ltd, Fresenius Se & Co. KGAA, Viatris Inc and among others.

Market Highlights

The Global Generic Drugs Market is estimated to register a CAGR of 9.36% during the forecast period and is estimated to reach USD 1,148.55 Billion by 2035.

The escalating prevalence of chronic diseases worldwide is acting as a significant catalyst for the expansion of the global generic drug market. With conditions like cancer, neurology, cardiovascular diseases, inflammatory diseases, and others on the rise, there's an amplified demand for cost-effective treatment options, compelling patients and healthcare providers to turn towards generic medications. Generic drugs, being bioequivalent to their brand-name counterparts but more affordable, offer a viable solution for managing chronic illnesses without burdening healthcare budgets. This burgeoning demand for generics is not only driven by patients seeking affordable therapies but also by healthcare systems and governments striving to contain healthcare expenditure while ensuring widespread access to essential medications.

The increase in the incidences of various types of cancer across the world is the major factor anticipating the growth of the market. Cancer is one of the leading causes of death globally, and the incidence of cancer is expected to continue rising in the coming years. This rise can be attributed to several factors such as an aging population, unhealthy lifestyle choices, environmental factors, and genetic predisposition. For instance, as per the World Health Organization, it was estimated that about 20 million new cancer cases were diagnosed in 2022. Furthermore, according to the Global Cancer Observatory, it was estimated that about 49.2% of cancer cases were diagnosed in Asia, 22.4% in Europe, 13.4% in Latin America. 7.8% in Caribbean and others (7.2%) in 2022.  Thus, surge in cancer cases has prompted researchers, pharmaceutical, and biotechnology companies to focus on developing and advancing cancer drugs to combat this deadly disease. For instance, in March 2024, Zydus Lifescience (India) launched anti-cancer generic drug olaparib in India. This drug has had been launched under the brand name of IBYRA in India, making advanced cancer treatment accessible to all.

Moreover, neurological diseases, such as Alzheimer's, Parkinson's, and epilepsy, are witnessing a surge in prevalence globally, driving up the demand for affordable treatment options. For instance, in February 2024, the World Health Organization reported that around 50 million people worldwide were suffering from epilepsy, and nearly 80% of people with epilepsy live in low- and middle-income countries. Also, in 2022, a Parkinson’s Foundation-backed study revealed that virtually 90,000 people are diagnosed with Parkinson’s disease each year in the US. Further, the Alzheimer’s Disease Foundation reported that there were around 50 million people living with dementia around the world in 2020.

Access Full Report @ https://www.marketresearchfuture.com/reports/generic-drugs-market-59410

Segment Analysis

The Global Generic Drugs Market has been segmented based on By Indication, By Route of Administration, By Distribution Channel .

Based on indication, the global generic drugs market is segmented into central nervous system, cardiovascular, urology, oncology, respiratory, and others. The oncology segment dominated the market in 2024, while the cardiovascular segment is projected to be the fastest-growing segment during the forecast period, 2025–2035.

The oncology segment emerged as the dominant indication in the global generic drugs market in 2024, accounting for the highest market share. This dominance is primarily attributed to the increasing global cancer burden, rising awareness about cancer treatment options, and the growing availability of low-cost generic oncology drugs. The high cost of branded oncology medications has created significant demand for cost-effective alternatives, making generic versions a crucial component in cancer care, especially in low- and middle-income countries.

Key factors driving the segment’s prominence include:

A surge in cancer incidence, with high prevalence of breast, lung, colorectal, and prostate cancer globally.

Expiration of patents on major branded oncology drugs, opening the market for biosimilars and small-molecule generics.

Government initiatives and reimbursement policies promote access to affordable cancer therapies.

Based on route of administration, the global generic drugs market is segmented into oral, tropical, parenteral, and others. The oral segment dominated the market in 2024, while the parenteral segment is projected to be the fastest-growing segment during the forecast period, 2025–2035.

The oral segment remains the largest contributor to the global generic drugs market and held a dominant share in 2024. Oral drug delivery is favored due to its ease of administration, patient compliance, cost-effectiveness, and non-invasiveness. This route is widely adopted for the administration of various therapeutic classes such as antibiotics, antidiabetics, antihypertensives, and analgesics.

Key factors driving the dominance of the oral segment include:

High patient preference for tablets, capsules, and syrups due to convenience.

Lower production and formulation costs compared to injectable or topical drugs.

Extensive use in chronic disease management, where long-term medication adherence is essential.

Availability of bioequivalent generic alternatives for a wide range of branded oral formulations.

Moreover, the segment benefits from strong regulatory support for generic oral drug approvals, especially under ANDA pathways (Abbreviated New Drug Applications) in major markets like the U.S. and Europe. The growing elderly population and expanding access to healthcare in emerging economies further strengthen the segment’s market presence.

Based on the distribution channel, the global generic drugs market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The online pharmacy segment dominated the market in 2024, while the retail pharmacy segment is projected to be the fastest-growing segment during the forecast period, 2025–2035.

The online pharmacy segment accounted for the largest share of the global generic drugs market in 2024, driven by the rapid digital transformation of the healthcare ecosystem and increasing consumer preference for convenient access to medications. The segment’s growth is underpinned by the rising penetration of e-commerce platforms, improved digital literacy, and wider smartphone and internet usage, especially in urban and semi-urban areas.

Key factors contributing to the segment’s dominance include:

Convenience of doorstep delivery and 24/7 availability of medicines.

Competitive pricing and frequent discounts on generic drugs.

Rising adoption during and post-COVID-19 pandemic, which accelerated the shift toward online healthcare services.

Availability of teleconsultation and e-prescription services, enabling a seamless digital medication fulfillment process.

Regional Analysis

Based on region, the global generic drugs market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest market share in 2024 and is anticipated to reach USD 487.36 billion by 2035.

However, Asia-Pacific is projected to grow at the highest CAGR of 11.10% during the forecast period. Major demand factors driving the North America market are North America held the largest share of the global generic drugs market in 2024 and is projected to reach approximately USD 487.36 billion by 2035. This dominant position is driven by the region’s well-established healthcare infrastructure, supportive regulatory frameworks, and high adoption rates of generic medicines across both retail and institutional settings. The U.S. contributes significantly, with its large patient population, increasing chronic disease burden, and efforts to reduce healthcare expenditure using generic alternatives.

Key Findings of the Study

• The Global Generic Drugs Market is expected to reach USD 1,148.55 Billion by 2035, at a CAGR of 9.36% during the forecast period.


• The Asia Pacific region accounted for the fastest growing in the global market.


• Based on Route of Administration, the Oral segment was attributed to holding the largest market in 2024.


• Sun Pharmaceutical Industries Ltd, Lupin Pharmaceuticals, Inc, Endo International Plc, Urobindo Pharma, Aspen Holdings, Cipla Ltd, Novartis Ag, Teva Pharmaceutical Industries Ltd, Fresenius Se & Co. KGAA, Viatris Inc and among others are the key market players.